Novel trifluoromethylated mono- and bicyclic succinimides derived from trifluoromethylmaleic
anhydride were synthesized using cyclopentadiene or 2,3-dimethylbutadiene and (het)arylamines.
The biological activity of these compounds was evaluated using prediction methods and experimental
studies. This series of new trifluoromethyl succinimides (3a,b and 6a-c) were tested by the National
Cancer Institute (NCI, Bethesda, USA) by Program NCI-60 DTP Human Tumor Cell Line Screen at a single
high dose (105 M). Imides revealed activity on Leukemia cell lines (RPMI-8226 - myeloma cell line),
Non-Small Cell Lung Cancer cell lines (A549/ATCC - lung carcinoma epithelial cells) and Renal cancer cell
lines (A498 and SN12 C).